Discovering innovative cancer therapies
From initial concept to the delivery of candidate drugs through to the clinic – Sentinel Oncology specializes in discovering cutting-edge treatments for oncology and diseases with a high unmet need
16,000
People in the UK diagnosed with a brain tumour each year
<5%
Of cancer drugs can readily access the brain
40%
Of all cancers will spread to the brain
20%
Of childhood cancers are in the brain
Founded in 2005 in Cambridge UK, Sentinel Oncology is dedicated to the development and commercialization of new therapeutics
Our core strength is the development of highly selective and targeted oncology candidate drugs. Our pipeline strategy is focused on the design and optimisation of new drugs which can be used to treat primary brain tumours or systemic tumours which frequently spread to the brain.
Meet the industry experts behind our research
The Sentinel Oncology team has extensive experience in drug research and development, coupled with a broad network of advisors and disease experts.
Discover our innovative scientific pipeline
The Sentinel Oncology portfolio includes three late-stage preclinical programs positioned to enter phase 1 clinical trials during 2023.
Our commercial & scientific partners
We collaborate with the world’s most forward-thinking scientific leaders and industry partners
See our latest news and events
